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Abstract The role of nitric oxide (NO) and guanosine 3',5'- 
cyclic monophosphate (cyclic GMP) in cellular regulation of en- 
dothelin-1 (ET-1) secretion was investigated in cultured porcine 
aortic endothelial cells. NO synthase was inhibited with N~-nitro - 
L-arginine (L-NNA) and guanylyl cyclase with the novel selective 
inhibitor, ODQ (1H-[1,2,4]oxadiazolo[4,3,-a]qninoxalin-l-one) 
(3 pM). Basal and phorbol ester (PMA)-stimulated ET-1 secre- 
tion were unaffected by ODQ, but stimulated secretion was in- 
creased by L-NNA. In the presence of the NO donors, sperminel 
NO, S-nitroso-glutathione (GSNO), and nitroprusside (NP) ET- 
I secretion was reduced, but ODQ had no effect on this inhibition, 
although it effectively inhibited cyclic GMP production. NO re- 
lease from donors, measured with a sensitive NO electrode, was 
greatest for spermine/NO, intermediate for GSNO, minimal for 
NP and paralleled inhibition of ET-1 secretion. The data suggest 
that in cultured endothelial cells, curtailment of ET-1 secretion 
is mediated by NO and independent of cyclic GMP. 
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1. Introduction 
Endothelin-1 (ET-1) is a recently discovered endothelium- 
derived polypeptide with potent vasoconstrictor activity [1]. 
Secretion of ET-1 by cultured endothelial cells is stimulated by 
several components of normal plasma [2,3], and inhibited by 
heparin [4], atrial natriuretic peptides [5], and prostacyclin [6,7]. 
Agents that mimic the effect of endothelium-derived NO and 
raise intracellular levels of cyclic GMP have been shown to 
reduce agonist-stimulated ET-I secretion [8]. 
The second messengers involved in inhibition of endothelial 
ET-1 secretion are not well understood. In cultured endothelial 
cells, NO [9] and/or cyclic GMP [10] may control ET-1 produc- 
tion, whereas in intact vessels inhibition was surmised to be due 
to cyclic GMP derived from smooth muscle cells. Shear stress- 
induced inhibition of ET-1 secretion was also attributed to 
NO-dependent elevations in cyclic GMP [11]. Exposure of cul- 
tured endothelial cells to hypoxia resulted in a considerable 
increase in ET-1 gene expression and peptide secretion, which 
were abolished in the presence of NP and potentiated by 
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L-NNA, an inhibitor of NO synthase [12]. These authors inter- 
preted their data as evidence for an active inhibitory role of 
NO, rather than cyclic GMP in ET-1 secretion. Recently, 8- 
bromo-cyclic GMP was found to be ineffective in inhibiting 
basal or stimulated ET-1 production in cultured human endo- 
thelial cells, and cAMP had a complex modulatory effect with 
both stimulatory and inhibitory pathways mediated by distinct 
protein kinases [13]. 
Due to its potent biological effects of ET-1, the inhibitory 
mechanisms of ET- 1 secretion are of considerable physiologic 
importance. To determine if cyclic GMP or NO, or both medi- 
ate(s) the suppression of ET-1 production, cyclic GMP produc- 
tion must be inhibited selectively, while leaving NO unaffected. 
This has been attempted with methylene blue [7,8,12], but can- 
not be achieved with this dye since it inhibits both guanylyl 
cyclase and NO synthase, as we have shown recently [14]. The 
other tool used in the above studies, inhibition of NO synthase 
by L-arginine derivatives, will reduce both endogenous NO and 
cyclic GMP levels, thus making it impossible to differentiate 
between the two putative mediators. Recently, a specific gua- 
nylyl cyclase inhibitor, ODQ without effects on NO synthase 
has become available [15]. Such a compound appears to be 
singularly useful in probing the role of cyclic GMP vs. NO in 
inhibition of ET-1 secretion. Therefore, the present study was 
designed: (i) to examine the effect of several NO-based vasodi- 
lators on ET-1 secretion; (ii) to determine the effect of ODQ 
on ET-I secretion and cyclic GMP levels; and (iii) to measure 
NO donor-derived NO release into the culture medium using 
a sensitive NO electrode and to compare NO levels with rates 
of ET-I release. 
2. Materials and methods 
2.1. Materials and solutions 
Spermine/NO was obtained from Midwest Research Institute, Kan- 
sas City, MO, USA. NP (sodium salt), nitrite (sodium salt), glutathi- 
one, 8-bromo-cyclic GMP, PMA, Ca 2÷ ionophore A23187, thapsi- 
gargin, L-NNA, 3',5'-cyclic nucleotide phosphodiesterase (PDE, from 
bovine heart) and superoxide dismutase (SOD) were purchased from 
Sigma Chemie, Vienna, Austria. ODQ was synthesized by Dr. E.B. 
Nielsen (Novo Nordisk A/S, Novo Nordisk Park, M~lov, Denmark). 
The anti-ET-1 antibody and ET-1 standards were from Peninsula Lab- 
oratories, Belmont, CA, USA. Dulbecco's minimum essential medium 
(DMEM) was from Life Technologies, Vienna, Austria. The source of 
all other chemicals and tissue culture media was described previously 
[16]. The following stock solutions were prepared [solvent]: spermine/ 
NO (10 mM, [10 mM NaOH]); PMA (1 mM, [DMSO]), thapsigargin 
(0.2 mM, [DMSO]), ODQ (100 mM, [DMSO]); A23187 (1 mM [etha- 
nol]); L-NNA (10 mM [HzO]), NP (1 mM [H20]). GSNO (10 raM) was 
prepared by mixing 0.1 ml glutathione (100 mM)+ 0.8 ml HC1 (I0 
mM) + 0.1 ml nitrite (100 mM). All stock solutions were stored at 
-20°C and diluted in distilled water or culture medium to the appropri- 
ate concentration just prior to the experiment (maximum water content: 
10%). 
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2.2. Cell cuhure and experimental protocol 
Porcine aortic endothelial cells were isolated and cultured as previ- 
ously described [17]. Only cells of first passage were used (~ 1 x 106 cells 
per well). For experiments, cells were incubated in fresh DMEM to- 
gether with all agents for 3 h at 37°C. ODQ (3/.tM) was added to the 
medium 15 min prior to NO donors [15]. To prevent cyclic GMP 
degradation, IBMX (1 mM) was also included. Following incubation, 
the media were harvested and frozen at -70°C pending analysis. 
2.3. Measurement of ET-1 and cyclic GMP 
ET-1 was measured by radio immunoassay (RIA) as previously de- 
scribed [17]. Briefly, thawed media were diluted with RIA-buffer 1 to 
5 and 0.1 ml was incubated with [3(~25I)Tyr]-ET-1 (0.1 ml, -10,000 
cpm/tube) and anti-ET-1 antibody (0.1 ml; RAS 6901) for 24 h at room 
temperature. To terminate incubation, 0.1 ml of ?,-globulin (11 mg/ml) 
and 0.75 ml of polyethylene glycol 6000 (20%) was added, and centri- 
fuged for 20 min to separate bound from free radioactivity. The pellet 
was counted in a gamma-counter (Packard Canberra, Vienna, Austria). 
Cyclic GMP was measured in culture media and cell lysates by RIA as 
described previously [18]. To determine whether esidual cyclic GMP 
in the presence of ODQ was of biological importance, cells were incu- 
bated in the additional presence of PDE (0.02 U/ml incubation medium) 
to completely remove the nucleotide. 
2.4. Electrochemical determination f NO 
The electrochemical determination of NO was performed with a 
Clark-type NO-sensitive lectrode (ISO-NO, World Precision Instru- 
ments, Mauer, Germany) as described previously [19]. Measurements 
were made at 37°C in a small glass vial containing 0.9 ml of DMEM 
and ~ 10 6 endothelial cells (baseline). The contents of the vial was con- 
stantly stirred. When the baseline was stable, 0.1 ml of the NO donor 
was added and the NO concentration recorded by an Apple Macintosh 
computer via an analogue-to-digital converter (MacLab, WissTech 
GmbH, Spechbach, Germany). 
2.5. Determination of cell viability 
Cell viability was determined morphometrically b  trypan blue exclu- 
sion and cell counting. In addition, lactate dehydrogenase (LDH) activ- 
ity was measured as described previously [20]. 
2.6. Presentation of results 
Group data are presented as arithmetic mean values + S.E.M. and 
were compared using the unpaired Student's t-test. All ET-1 secretion 
data were calculated as secretion rates (pg/3 h and ~ 10 6 cells) and are 
presented as a percentage of control secretion which is indicated in the 
figures. The time course of NO measurements (inset of Figs. 4 and 5) 
was directly transcribed from the MacLab disc file. A P < 0.05 was 
considered as significant. P < 0.01 or lower were not indicated sepa- 
rately. The number of culture dishes is indicated as n. 
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Fig. 1. ET-1 secretion into culture medium under basal and stimulated 
conditions (PMA; 0.4 ¢tM). Stimulated secretion was increased by L- 
NNA (0.1 mM); P < 0.05). Data are means + S.E.M., n = f~9. Refer- 
ence (100%): 327 + 12 pg/3 h. *P < 0.05 vs. Control (PMA). 
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Fig. 2. Effect of ODQ (3 ,uM) on spermine/NO-induced inhibition of 
ET-1 secretion (upper panel) and cyclic GMP accumulation (lower 
panel). (A) In the absence of PDE and presence of IBMX (1 mM). (B) 
In the presence of PDE (0.02 U/ml) and absence of IBMX. Note the 
complete removal of cyclic GMP and unchanged ET-1 secretion in (B). 
*P< 0.05 vs. baseline; aP< 0.05, ODQ vs. Control. Data are 
means + S.E.M., n = 6 (A) and n = 3 (B). Reference (100%): 1.4 + 0.4 
pmol/3 h cyclic GMP; for ET-I, see Fig. 1. 
3. Results 
Fig. 1 illustrates the effect of NO synthase and guanylyl 
cyclase inhibit ion on basal and stimulated ET- 1 secretion. Basal 
ET-1 secretion into culture medium measured over 3 h was 
unaffected by either enzyme inhibitor (P > 0.05). The phorbol  
ester PMA (0.4 ¢tM) stimulated ET-1 secretion by 35% as we 
have shown previously [17]. Inhibit ion of guanylyl cyclase with 
ODQ had no effect on stimulated ET-1 secretion (P > 0.05), but 
blocking NO synthase with L-NNA (0.1 mM) slightly increased 
ET-1 secretion rate (17%; P < 0.05 vs. Control). The cell-per- 
meant cyclic GMP derivative, 8-bromo-cyclic GMP (0.1 mM),  
had no effect on ET-1 secretion (P > 0.05, n = 6; data not 
shown). 
Fig. 2 illustrates the effect of spermine/NO, which releases 
NO in a controlled fashion [21], on ET-1 secretion and cyclic 
GMP accumulation i  the culture medium. ET-1 secretion and 
cyclic GMP product ion were inhibited in a concentration-de- 
pendent manner, but not at matched concentrations. In the 
presence of ODQ, cyclic GMP accumulation was greatly re- 
duced at all concentrat ions of spermine/NO, but ET-1 secretion 
was unchanged compared to Control  (P > 0.05, Fig. 2A). A 
possible role for cyclic GMP in suppression of ET-1 synthesis 
observed at 0.1 and 1 mM spermine/NO was examined by 
co-incubating cells with PDE to immediately degrade any cyclic 
nucleotide produced (Fig. 2B). The same inhibitory pattern of 
ET-1 accumulation was observed espite complete removal of 
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Fig. 3. Effect of ODQ (3/zM) on inhibition of ET-I secretion (A) and 
cyclic GMP accumulation (B) induced by nitroprusside (1 mM), thapsi- 
gargin (100 nM), and A23187 (1/.tM). * P < 0.05 vs. baseline; #P < 0.05, 
ODQ vs. Control. Data are means + S.E.M., n = 6. For reference val- 
ues see Fig. 2. 
cyclic GMP, and the degree of inhibition was identical to that 
in the absence of PDE. A similar mismatch between inhibition 
of ET-1 secretion and cyclic GMP levels was also observed with 
the organic nitrate, NP [22] (1 mM) and two experimental 
agents known to stimulate cyclic GMP production via in- 
creased intracellular free Ca 2+ [17], thapsigargin (0.1 ¢tM) and 
the Ca 2+ ionophore A23187 (1 ¢tM) (Fig. 3). However, whereas 
the latter two compounds reduced ET-1 secretion to 60% and 
38% of control, respectively NP had no effect (P > 0.05). All 
three compounds increased cyclic GMP levels, and ODQ pre- 
vented these increases, but it was again without effect on inhi- 
bition of ET-I secretion. Similarly, in the presence of 1 mM 
GSNO [14,23], ET-1 secretion was inhibited by 45% and cyclic 
GMP production was stimulated 23-fold. ODQ was without 
effect on ET-1 levels in the culture medium (P > 0.05), but 
potently reduced cyclic GMP generation (n = 6; data not 
shown). Control incubations with glutathione orspermine were 
without effect on ET-1 secretion and cyclic GMP accumulation 
(n = 3). 
The release of NO from spermine/NO is shown in Fig. 4. At 
100 ¢tM parent compound, the NO concentration measured in 
culture medium was ~4¢tM. Between 100¢tM and 600¢tM, NO 
release increased linearly; at 1 mM (outside linear portion of 
calibration), the NO concentration reached was -20-25/~M. 
Following a bolus concentration f 100/.tM spermine/NO, NO 
release was rapid in onset and maintained above 1 ~M for the 
entire incubation period of 3 h (inset in Fig. 4). By contrast, 
release of NO from NP (Fig. 5) was very small: upon addition 
of 1 10 mM NP, concentrations u ed in pharmacological ex- 
periments, less than 0.5 ¢tM NO was measured; a maximum of 
~2.5 ¢tM was achieved with 100 mM NP. No NO was detected 
at NP concentrations below 1 mM. Although NO release from 
this donor was also rapid in onset, it was short-lasted (~ 10 min; 
inset in Fig. 5). The low levels of NO were not due to metabo- 
lism of NO to superoxide anion because SOD (2,500 U/ml) was 
without effect (n = 3; data not shown). For GSNO (0.1-I raM) 
peak NO levels achieved were comparable to those measured 
for spermine/NO (data not shown). 
Because of the potentially toxic effects of micromolar con- 
centrations of NO observed in a vaiety of different cells, the 
viability of endothelial cells at the end of the incubation period 
was evaluated. No changes were noticeable in the general ap- 
pearance of cells, nor in their capacity to accumulate trypan 
blue or release LDH (data not shown). 
4. Discussion 
The present study demonstrates that inhibition of ET-I re- 
lease by NO-containing compounds cannot be reversed by se- 
lective inhibition of guanylyl cyclase, indicating that ET-1 se- 
cretion is not regulated by cyclic GMP. Of the three NO donors 
tested, only those reduced ET-1 secretion which also released 
measurable amounts of NO (spermine/NO, GSNO), whereas 
NP showed no inhibitory effect on ET-1 secretion and released 
no NO. This suggests that the active inhibitory principle is NO 
or NO-derived. 
Nitrovasodilators such as NP and GSNO are well known to 
activate NO-dependent soluble guanylyl cyclase and increase 
tissue cyclic GMP levels [24]. These compounds have been 
suggested to attenuate ET-1 secretion via a mechanism involv- 
ing the NO/cyclic GMP system (see section 1). In the present 
experiments, they also potently (-> 1 ¢tM) stimulated cyclic 
GMP production of cultured endothelial cells, but were only 
weak inhibitors of ET-1 secretion. The involvement of cyclic 
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Fig. 4. Release of NO from spermine/NO into culture medium (pH 7.4, 
37°C). The values represent the maximum concentration attained after 
a given addition of spermine/NO. Data are means + S.E.M., n = 3. 
(Inset) Kinetics of NO release following a single addition of 100/IM 
spermine/NO tothe reaction vial (single xperiment). 
E Brunner et al./FEBS Letters 376 (1995) 262-266 265 
::t. 
2 
~D 
© 
Z 
0 
~T~ A 
/ \ 
0 15 30  
Time (rain) 
I I 
o 16o 15o 200 
Nitroprusside (mM) 
Fig. 5. Release of NO from nitroprusside into culture medium (n = 3). 
The values represent the maximum concentration attained after a given 
addition of nitroprusside. Data are means + S.E.M., n = 3. (Inset) Ki- 
netics of NO release following a single addition of 10 mM nitroprusside 
to the reaction vial (single experiment). 
GMP in this inhibition was probed using the novel guanylyl 
cyclase inhibitor, ODQ which is a specific inhibitor of NO- 
sensitive GC without effect on particulate guanylyl cyclase or 
adenylyl cyclase, as was shown previously [15]. Hence, this 
compound is singularly useful in determining the contribution 
of endogenous cyclic GMP in regulating ET-1 secretion. ODQ 
potently antagonized basal and agonist-induced cyclic GMP 
production without affecting ET-1 secretion rates (Figs. 2 and 
3). Furthermore, the complete removal of cyclic GMP by PDE 
resulted in no change in the spermine/NO-induced inhibition 
of ET-1 secretion. This is strong evidence that the inhibitory 
effect on ET-I secretion, at least of the agonists tested here, is 
not mediated by cyclic GMR The same conclusion was reached 
using 8-bromo-cyclic GMP, confirming a recent report dealing 
with human endothelial cells [13]. Previous reports ascribing an 
inhibitory role to cyclic GMP using methylene blue do not 
contradict our conclusion, because this dye, besides blocking 
guanylyl cyclase, inhibits nitric oxide synthase at even higher 
potency than guanylyl cyclase [14]. Moreover, the dye stimu- 
lates the production of superoxide anion [25]. Both these ac- 
tions will reduce the tissue NO concentration, so that the ob- 
served effect of methylene blue could also be due to changes 
in NO rather than cyclic GMP levels. 
Our suggestion of an NO-mediated inhibition of ET-1 secre- 
tion is supported by the increase in ET-1 secretion following 
blockade of NOS by L-NNA and the measurements of donor- 
derived NO levels in culture medium. This conclusion is 
strengthened bythe fact that control compounds (spermine and 
glutathione) did not affect ET-1 secretion and produced no 
measurable NO. Interestingly, a similar conclusion was reached 
recently using L-NNA [12], although this inhibitor cannot dif- 
ferentiate between a regulatory effect mediated by decreasing 
endogenous NO as opposed to cyclic GMP levels. Given the 
present evidence, in their study L-NNA probably reduced ET-1 
levels by lowering endogenous NO production and not via 
reduced cyclic GMP levels. The reasons for the inconsistent 
effect of nitric oxide synthase inhibition on basal ET-1 secretion 
rates are not clear. The inhibition of basal ET-I secretion re- 
ported by Kourembanas etal. [12] following 24 h of incubation 
with L-NNA (2.5 mM) was not consistently observed in the 
present and a previous study [17] using cultured cells, nor in 
several other ones using native endothelial cells [9] and whole 
blood vessels [8]. The reasons may include differences in incu- 
bation time (24 h in [12] vs. 3-6 h in the other studies), quality 
of cells (6th to tenth passage [12] vs one passage or native cells), 
and different levels of [Ca2+]i which we have recently shown to 
affect basal ET-1 secretion rates [20]. 
Our measurements of NO released from several NO donors 
explain the differing potency of NO donors in inhibiting ET-1 
release. Thus, NP was entirely ineffective at 1 mM, and no NO 
release was detectable under our experimental conditions. On 
the other hand, the activation of guanylyl cyclase is probably 
mediated by NP itself (parent compound) and not by NO re- 
leased from it as suggested previously [26]. Both spermine/NO 
and GSNO reduced ET-1 secretion, but spermine/NO was 
more potent, possibly reflecting the higher NO concentration 
attained in the culture medium with this compound. The inhib- 
itory action of NO on ET-1 secretion was in all probability a
specific effect and not due to NO-induced cell-toxicity as judged 
by several standard criteria of cell viability [20,27]. The reason 
for the low absolute potency of all NO donors tested is un- 
known; too short an incubation time cannot account for their 
weak inhibitory effects, since peak NO levels were reached early 
and similar results were obtained following 5 h of incubation 
(data not shown). 
The inhibitory effect of increased levels of [Ca2+]i on ET-1 
secretion has been addressed previously [17]. As expected, cy- 
clic GMP levels were also increased under these conditions, but 
inhibition of ET-1 secretion was similarly unaffected by ODQ 
as with NO donors (Figs. 2 and 3). Hence, cyclic GMP seems 
to be involved neither in NO donor nor CaZ+-mediated inhibi- 
tion of NO release. 
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